SERPINF1 and age-related macular degeneration: Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (TargetAMD) has shown to genetically modify iris pigmented epithelial (IPE) cells or retinal pigmented epithelial (RPE) cells that overexpress PEDF to provide a long-lasting cure of AMD.